Verastem, Inc. (VSTM)
| Market Cap | 489.25M |
| Revenue (ttm) | 88.52M |
| Net Income (ttm) | -67.73M |
| Shares Out | 153.33M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $2.88 |
| Previous Close | $2.85 |
| Change ($) | 0.03 |
| Change (%) | 1.05% |
| Day's Open | 2.82 |
| Day's Range | 2.79 - 2.92 |
| Day's Volume | 1,404,869 |
| 52-Week Range | 1.08 - 3.20 |
Penny stocks are back in a big way; which 3 should you watch? The post Penny Stocks Are Back; Here's 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported fi...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
The biotech's chief medical officer has stepped down just two weeks after joining the company.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
Verastem has recently raised non-dilutive capital to bring two assets into phase 2 trials. The company's lead asset has the potential to address around 30% of all cancers and be combined with other medi...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported fin...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced ne...
Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced up...
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...
The biotech company reported second-quarter earnings and sold some drug development rights.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verastem: A Growth Story In The Biotechnology Sector
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.
Is (VSTM) Outperforming Other Medical Stocks This Year?
Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.
Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.
Investors are excited about an upcoming conference call to discuss clinical data from patients with KRAS-mutation positive tumors.
Verastem (VSTM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Verastem Oncology: An Undervalued KRAS Oncology Play
Healthcare bargain hunters can find good values in quality low-priced stocks.
Is (VSTM) Outperforming Other Medical Stocks This Year?
Verastem has been struggling lately, but the selling pressure may be coming to an end soon.
As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM).
Verastem: Outlook For 2020-21
Verastem: Still Bullish After Chugai Pharmaceutical Deal
Billionaire investor Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed earlier this week his firm established a new 14.91% stake in Verastem Inc.
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Verastem: Earnings Beat And Executing 6-2-5 Plan Trigger Unjustified Sell-Off
Verastem, Inc. (VSTM) CEO Brian Stuglik on Q3 2019 Results - Earnings Call Transcript
Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem Oncology's share price continues to flatline as we approach the end of 2019. The market appears to have branded COPIKTRA's launch as a dud.
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
Verastem, Inc. (VSTM) CEO Brian Stuglik on Q2 2019 Results - Earnings Call Transcript
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactin... [Read more...]
| Industry Biotechnology | IPO Date Jan 27, 2012 |
| CEO Brian Stuglik | Employees 48 |
| Stock Exchange NASDAQ | Ticker Symbol VSTM |
Financial Performance
In 2020, Verastem's revenue was $88.52 million, an increase of 407.08% compared to the previous year's $17.46 million. Losses were -$67.73 million, -54.61% less than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for Verastem stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 56.25% from the latest price.